Cargando…

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. The Modified Vaccinia Ankara (MVA) vector system is being explored as a platform for development of multiple vaccines. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volkmann, Ariane, Williamson, Anna-Lise, Weidenthaler, Heinz, Meyer, Thomas P.H., Robertson, James S., Excler, Jean-Louis, Condit, Richard C., Evans, Eric, Smith, Emily R., Kim, Denny, Chen, Robert T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd. 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568176/ https://www.ncbi.nlm.nih.gov/pubmed/33077299 http://dx.doi.org/10.1016/j.vaccine.2020.08.050

Ejemplares similares

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
por: Condit, Richard C, et al.
Publicado: (2020)

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
por: Kochhar, Sonali, et al.
Publicado: (2020)

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines
por: Kochhar, Sonali, et al.
Publicado: (2020)

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines
por: Kim, Denny, et al.
Publicado: (2020)

Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE(®) against aerosolized rabbitpox virus in a rabbit model()
por: Garza, Nicole L., et al.
Publicado: (2009)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014)

Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines
por: Gurwith, Marc, et al.
Publicado: (2020)

The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG)
por: Chen, Robert T., et al.
Publicado: (2021)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
por: Jordan, Ingo, et al.
Publicado: (2013)

Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
por: Goossens, Martine, et al.
Publicado: (2013)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified Vaccinia virus Ankara (MVA)
por: Marcacci, Maurilia, et al.
Publicado: (2020)

Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA)
por: Klaas, Lioba, et al.
Publicado: (2021)

Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
por: Cottingham, Matthew G., et al.
Publicado: (2008)

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
por: Frey, Sharon E., et al.
Publicado: (2015)

Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model
por: Julander, Justin G., et al.
Publicado: (2018)

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus
por: Hernandez, Libia Milena, et al.
Publicado: (2022)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
por: Cottingham, Matthew G., et al.
Publicado: (2011)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Nave, Lior, et al.
Publicado: (2023)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)
por: Chiam, Rachael, et al.
Publicado: (2009)

Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells
por: Peng, Chen, et al.
Publicado: (2020)

Early viral protein synthesis is necessary for NF-κB activation in modified vaccinia Ankara (MVA)-infected 293 T fibroblast cells
por: Martin, Stefani, et al.
Publicado: (2009)

Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion
por: Song, Guang-Yun, et al.
Publicado: (2011)

Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
por: Currier, Jeffrey R., et al.
Publicado: (2010)

Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccines Efficiently Protect Cockatiels Against Parrot Bornavirus Infection and Proventricular Dilatation Disease
por: Rall, Isabell, et al.
Publicado: (2019)

A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA)
por: Jordan, Ingo, et al.
Publicado: (2019)

Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome
por: Delaloye, Julie, et al.
Publicado: (2009)

SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells
por: Liu, Ruikang, et al.
Publicado: (2019)

Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen
por: Knudsen, Maria L., et al.
Publicado: (2015)

Retraction: Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome
Publicado: (2022)

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273)
por: Leav, Brett, et al.
Publicado: (2022)

One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
por: Ilchmann, Heiko, et al.
Publicado: (2022)

Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)
por: Eggers, Maren, et al.
Publicado: (2015)

Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015)

Purification of modified vaccinia virus Ankara from suspension cell culture
por: Jordan, Ingo, et al.
Publicado: (2015)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Orlova, Olga Vladimirovna, et al.
Publicado: (2022)

Modified vaccinia Ankara–Bavarian Nordic vaccine against mpox in children
por: Turtle, Lance, et al.
Publicado: (2023)

A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model
por: Castillo-Olivares, Javier, et al.
Publicado: (2011)

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
por: Kaufman, Howard L, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_m6e8pm5kiiffn0hca8sfjtp4i4